The cyclic hypothalamic tetradecapeptide, growthhormone release-inhibiting hormone (GH-RIH), somatostatin, inhibits the secretion of growth hormone (Brazeau et al., 1973) and TSH (Hall et al., 1973) from the anterior pituitary, as well as insulin (Alberti et al., 1973) and glucagon from the pancreas. More recently, somatostatin has been found markedly to suppress the release of gastrin in normal subjects and patients with the Zollinger-Ellison syndrome . The first nonendocrine effects of somatostatin to be demonstrated were direct inhibition of gastric acid secretion in dogs (Barros D'Sa et al., 1975a) and of acid and pepsin in cats . Similar inhibition by somatostatin of gastric acid and pepsin has been found in response to betazole in man (Lankisch et al., 1975) , pentagastrin in man , and dog (Konturek et al., 1976) and in response to histamine, peptone, and urecholine in dogs (Konturek et al., 1976) . Recent morphological studies have demonstrated somatostatin in the islet cells of the pancreas (Luft et al., 1974) and localised in the D cells of the pancreas, the stomach, and the duodenum (Polak et al., 1975) .
In view of reported effects of somatostatin such as thrombocytopenia (Ricketts, 1975) , impaired platelet aggregation Goodner, 1975) , with increased concentrations of the fibrin degradation product FgE in man (Lancet, 1975) to perform further studies in dogs rather than in man. These experiments were designed to test the effects of somatostatin on gastric acid, gastrin and pepsin in response to insulin hypoglycaemia, a meat meal, histamine, and pentagastrin.
Methods
Four trained dogs (25-30 kg) with previously fashioned gastric fistulae were studied after an overnight fast. Blood samples were drawn from a venous catheter and 0-9% saline or somatostatin infusion given into a superficial leg vein. Pure synthetic cyclic somatostatin was used (Baychem Ltd) and was infused in 0 9 % saline in concentrations in the range 0 5-32,ug/kg h.
During histamine and pentagastrin-stimulated experiments somatostatin was infused in the second hour of a three hour infusion of submaximal doses of histamine acid phosphate (0 5 ,ug/kg-min) and pentagastrin (1 pg/kg-h). In the insulin experiments insulin 0-2 u/kg was given as a single intravenous injection, and somatostatin (5 or 8 ug/kg h) infused for 30 minutes before and 90-120 minutes after the insulin injection. Fifteen minute collections of gastric juice were made and the volume and titratable acidity (to pH 7) were measured. Pepsin concentration was measured by an Autoanalyzer method (Vatier et al., 1968) using haemoglobin as a substrate (Anson and Mirsky, 1932) . Blood samples were also taken every 15 minutes for measurements of plasma glucose and gastrin. Glucose was measured by the glucose oxidase method of Wincey and Marks (1961) adapted for an Autoanalyzer. Plasma immunoreactive gastrin was measured by radioimmunoassay 315 A. A. J. Barros D'Sa, S. R. Bloom, and J. H. Baron (Russell et al., 1976 ) using antiserum Gas 8 which is sensitive to changes in human G-17 of 1-5 pmol/l, reacts 50% with G34, but has no affinity for pentagastrin or big big gastrin.
During meal-stimulated experiments somatostatin was given intravenously in the first two hours of a three hour experiment and acid output was measured by the technique of intragastric titration with sodium bicarbonate (Fordtran and Walsh, 1973) modified for the dog (Barros D 'Sa et al., 1975b) . The meal consisted of Lassie meat (20 g/kg). Plasma gastrins were also measured.
Results (Table) INSULIN Dogs 1 and 2 were infused with 8 pg/kg h somatostatin ( Fig. 1 ) and dogs 3 and 4 with 5 ,ug/kg h (Fig. 2) . The mean degree of hypoglycaemia after insulin during the control infusion of saline was not significantly different from that seen after insulin during somatostatin infusion and there was no observable difference in the behaviour of the dogs on the two occasions. The mean gastrin increment was inhibited by 70% after the lower dose and 86% after the higher dose of somatostatin, almost identical with the inhibition of insulin-stimulated acid output of 74% and 85 % after these doses. MEAL (Fig. 3 ) Inhibition of acid output was greater with increasing doses of somatostatin. With the lowest dose of 0-5 /g/kg-h there was a rebound in secretion after the somatostatin infusion was stopped, with the acid output exceeding control levels. During the two-hour infusion with higher doses of 1 pg/kg-h, gastric acid was totally inhibited in every dog with some return of secretion after stopping the infusion. Acid secre- Kug/kg h. The inhibition by somatostatin of mealstimulated gastrin was also dose dependent (Fig. 4) . In all experiments except when the lowest dose of somatostatin was used there was a marked depression in plasma gastrin levels with a definite rise after the somatostatin infusion was stopped. The recovery phase of gastrin after stopping somatostatin was also dose dependent, with the least recovery with higher doses of somatostatin.
Pepsin data are difficult to interpret because of the initial washout rise of pepsin after histamine followed by a fall and rise. Pepsin outputs after somatostatin were inhibited less than acid outputs (Table) .
HISTAMINE
Acid output was depressed by somatostatin in histamine experiments (Fig. 5) .
PENTAGASTRIN
Pentagastrin-stimulated acid output decreased immediately and rapidly after somatostatin was infused (Fig. 6 ). Acid output was reduced by 94% and pepsin output reduced by 76%. There was some recovery in acid output and marked recovery in pepsin output after the somatostatin infusion was stopped.
Basal plasma gastrin This was not affected by the infusions of histamine or pentagastrin. During the somatostatin infusion these still basal plasma levels were depressed with some recovery after the somatostatin infusions were stopped (Figs. 5 and 6). [U-E] indicates GH-RIH 32 ug/kg-h. , and in hypergastrinaemic patients with pernicious anaemia and a gastrinoma .
The relationship of gastrin release to gastric acid secretion after hypoglycaemia is complex (Cowley et al., 1973) . In man the peak plasma gastrin after insulin hypoglycaemia precedes the peak acid output by 15 to 30 minutes (Cowley et al., 1973 ) and a similar delay was seen in dogs ( Figs. 1 and 2 ), suggesting that the vagally released gastrin could indirectly prime the parietal cells to respond to direct cholinergic vagal stimulation.
In the meal experiments there was a tendency for gastric acid and plasma gastrin to rebound after the infusions of low doses of somatostatin were stopped. In the histamine, insulin, and pentagastrin experiments there was some recovery in acid output after the inhibitory influence of somatostatin was removed but there was no rebound , nor has a rebound rise been seen in the hormone secretion of patients with hormone secreting tumours after stopping somatostatin Bloom et al., 1974) .
Histamine-and pentagastrin-stimulated pepsin was inhibited by somatostatin to a similar degree as inhibition of acid. Inhibition by somatostatin of acid and pepsin secretion in response to histamine stimulation was less marked than its effect on pentagastrin-stimulated acid and pepsin secretion.
Somatostatin inhibits the release of acid, pepsin, and gastrin from parietal, chief, and G-cells in response to a meal, of acid and gastrin in response to insulin, and of acid and pepsin in response to pentagastrin and histamine. The physiological significance of this inhibition remains uncertain. Somatostatin has not been detected in peripheral blood, so that it is unlikely to be a circulating hormone. However, the wide distribution of somatostatin in the alimentary system could allow it a paracrine role as a local chemical regulator of exocrine as well as endocrine secretion. 
